Logo image
Epidemiology and Treatment Patterns of Pediatric Orbital Embryonal Rhabdomyosarcoma in the United States
Journal article

Epidemiology and Treatment Patterns of Pediatric Orbital Embryonal Rhabdomyosarcoma in the United States

Sachin Pathuri, Jainam Shah, Joshua Ong, Ibrahim Furkan Acar, Peter Silberstein, Kourosh Shahraki, Karl Golnik, Andrew Lee and Donny W. Suh
Ocular oncology and pathology
10/22/2026

Abstract

Introduction This study examined associations between race/ethnicity, geographic classification, and median household income with treatment allocation as well as treatment initiation among pediatric patients with orbital embryonal rhabdomyosarcoma (RMS) in the U.S. Methods We conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) program, which includes 18 registries representing approximately 46% of the U.S. population. Children <15 years of age diagnosed between 2000 and 2021 with orbital embryonal RMS were included. Outcomes included receipt of surgery, radiation therapy (RT), and chemotherapy. Binary logistic regression models provided adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for treatment option receipt. Multiple linear regression assessed predictors of time to treatment initiation. Results Of 113 eligible patients, 67 (59.29%) were Non-Hispanic White, 102 (89.16%) resided in metropolitan counties, and 93 (82.69%) were from counties with median household income ≥$60,000. Most patients received chemotherapy (n = 108, 95.58%) and RT (n = 102, 90.27%), and 59 (52.21%) patients underwent surgery. Non-Hispanic White patients had higher odds of receiving RT than Non-White patients (aOR: 5.328; 95% CI: 1.163–14.403; P = 0.009). Chemotherapy was more accessible to patients residing in metropolitan counties (aOR: 14.811; 6.220–25.920; P < 0.001). Age at diagnosis was a significant predictor of time to treatment (P = 0.017). Age at diagnosis was distributed as follows: <1 year (n = 4, 3.54%), 1–4 years (n = 35, 30.97%), 5–9 years (n = 48, 42.48%), and 10–14 years (n = 26, 23.01%). Conclusion Ethnoracial and geographic disparities were observed and may affect access to RT and chemotherapy in children with orbital embryonal RMS. Age at diagnosis was a significant predictor of time to treatment initiation, a finding that warrants further investigation. Efforts to address structural barriers to equitable multimodal care are needed.

Metrics

1 Record Views

Details

Logo image